Scpharmaceuticals 2025 Q1 Earnings Misses Targets as Net Loss Widens 39.9%

Scpharmaceuticals (SCPH) reported its fiscal 2025 Q1 earnings on May 14th, 2025. Despite the substantial revenue growth of 92.6%, the company fell short of expectations with a net loss of $19.74 million, a 39.9% increase from the previous year's loss. The guidance remains in line, with expectations for quarterly net cash outflows to decrease as revenues rise. Scpharmaceuticals continues to navigate financial challenges while focusing on product expansion and market penetration.

Revenue

Scpharmaceuticals' revenue surged by 92.6% year-over-year, reaching $11.75 million in the first quarter of 2025. The primary driver of this increase was FUROSCIX®, which contributed significantly to the company's overall revenue performance.

Earnings/Net Income

Scpharmaceuticals reported a deepened loss of $0.37 per share in Q1 2025 compared to $0.36 per share in Q1 2024. The net loss expanded by 39.9% to $19.74 million. The continued losses indicate ongoing challenges in achieving profitability.

Price Action

The stock price of Scpharmaceuticals has dropped 4.27% during the latest trading day, has dropped 7.05% during the most recent full trading week, and has dropped 3.45% month-to-date.

Post Earnings Price Action Review

Investors have explored strategies that tap into potential long-term growth opportunities following Scpharmaceuticals’ earnings report. Historically, buying SCPH shares when revenues miss expectations and holding them for 30 days has yielded a 20.45% return. This approach outperforms a shorter-term 10-day strategy, which provides a 14.87% return. The strategy suggests optimism for sustained growth, especially with Scpharmaceuticals’ recent expansion into the Chronic Kidney Disease (CKD) market and the positive trajectory of FUROSCIX®. The company’s strategic focus on Medicare patient dynamics and autoinjector development further supports the potential for improved performance. Despite seasonal challenges, Scpharmaceuticals aims to leverage these trends for future success.

CEO Commentary

John Tucker, Chief Executive Officer, emphasized that scPharmaceuticals is better positioned than ever, with FUROSCIX successfully penetrating the market by keeping patients at home and away from hospitals. He noted a strong Q1 performance with $11.8 million in revenue and the filling of approximately 13,800 FUROSCIX doses, despite seasonal challenges. Tucker highlighted the positive trajectory of fill rates as more Medicare patients reach their out-of-pocket caps, asserting that the CKD market expansion and Autoinjector development will drive future growth. He expressed optimism about FUROSCIX's long-term prospects, stating, “we believe FUROSCIX is well-positioned to treat heart failure and kidney disease patients.”

Guidance

scPharmaceuticals anticipates a blended gross-to-net discount for FUROSCIX of approximately 30% over the balance of 2025. The company expects quarterly net cash outflows to decrease for the remainder of 2025 as revenues rise and outflows normalize. Tucker expressed confidence in the ability to scale effectively and deliver value, indicating momentum in prescriptions and fill rates, particularly as more patients benefit from reduced out-of-pocket costs under Medicare.

Additional News

Recently, scPharmaceuticals announced its participation in three upcoming investor conferences in May 2025, showcasing its commitment to investor engagement and transparency. CEO John Tucker will present at the Citizens Life Sciences Conference, the H.C. Wainwright 3rd Annual BioConnect Investor Conference, and the Craig-Hallum 22nd Annual Institutional Investor Conference. These events aim to provide insights into the company’s strategic initiatives and future plans. Additionally, scPharmaceuticals has received FDA approval for its supplemental New Drug Application to expand FUROSCIX®’s indication to include the treatment of edema in chronic kidney disease patients. This approval marks a significant milestone in broadening the product's application and enhancing its market potential.